Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?

Saved in:
Bibliographic Details
Published in:Journal of infection and public health 2024-09, Vol.17 (9), p.102512, Article 102512
Main Authors: Bang, Line Lundegaard, Madsen, Lone Wulff, Pedersen, Rune Micha, Nilsson, Anna Christine, Johansen, Isik Somuncu, Andersen, Thomas Emil
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - blood
COVID-19
COVID-19 - immunology
COVID-19 Drug Treatment
Humans
In vitro neutralization
Monoclonal antibodies
Neutralizing antibodies
SARS-CoV-2
SARS-CoV-2 - immunology
Sotrovimab
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1876-0341
1876-035X
1876-035X
DOI:10.1016/j.jiph.2024.102512